LoratadineThird Party Manufacturing in India

Loratadine is a long-acting, second-generation tricyclic antihistamine that selectively antagonizes peripheral histamine H1 receptors. When allergens trigger the release of histamine from mast cells and basophils, histamine binds to H1 receptors on respiratory smooth muscle, vascular endothelial cells, and immune cells, producing symptoms such as sneezing, itching, rhinorrhea, and urticaria. Loratadine competes with free histamine for these receptor sites, blocking the downstream inflammatory cascade. Unlike first-generation antihistamines, loratadine has minimal penetration of the blood-brain barrier due to P-glycoprotein-mediated efflux, which significantly reduces central nervous system sedation. It also exhibits a higher affinity for peripheral H1 receptors than central H1 receptors. The onset of action occurs within one to three hours, and the effect persists for 24 hours, allowing once-daily dosing. Loratadine has negligible anticholinergic activity and does not demonstrate clinically significant alpha-adrenergic blockade.

Therapeutic Uses

Loratadine is indicated for the symptomatic relief of allergic conditions:

• Seasonal Allergic Rhinitis: Relieves sneezing, nasal itching, rhinorrhea, and ocular itching and burning associated with hay fever and pollen allergies.
• Perennial Allergic Rhinitis: Manages year-round allergy symptoms triggered by dust mites, pet dander, moulds, and other indoor allergens.
• Chronic Idiopathic Urticaria: Reduces pruritus, erythema, and the number and size of hives in patients with chronic urticaria of unknown cause.
• Allergic Dermatologic Disorders: Provides relief from itching and skin reactions associated with allergic skin conditions.

Why Manufacturers Choose Loratadine

Loratadine is one of the highest-volume antihistamine molecules globally, with consistent demand across retail pharmacy chains, hospitals, and export markets. Its OTC status in most countries, including India and the United States, drives massive consumer volumes that translate into steady manufacturing orders. Indian manufacturers benefit from established supply chains for the API, multiple dosage form options (tablets, oral liquids, orally disintegrating tablets), and the molecule's inclusion in WHO Essential Medicines List. The low incidence of sedation and favourable safety profile make it a preferred first-line antihistamine for all age groups, ensuring sustained market relevance.

This makes Loratadine one of the most sought-after molecules for third party manufacturing in India, with high-volume demand from PCD franchise operators, hospital tenders, and export-oriented pharmaceutical companies.